{"id":21823,"date":"2024-11-22T20:09:46","date_gmt":"2024-11-22T07:09:46","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=21823"},"modified":"2024-12-22T17:22:15","modified_gmt":"2024-12-22T04:22:15","slug":"understanding-ighv-mutational-status-in-chronic-lymphocytic-leukaemia-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=21823","title":{"rendered":"Understanding IGHV Mutational Status in Chronic Lymphocytic Leukaemia (CLL)"},"content":{"rendered":"<p><span style=\"color: #333333;\">This document here, <a style=\"color: #333333;\" href=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2024\/12\/IGHV-patient-information.docx\" target=\"_blank\" rel=\"noopener\">IGHV Mutational Status Testing in Chronic Lymphocytic Leukaemia<\/a> explains the role of IGHV mutational status testing in CLL and its impact on treatment in the New Zealand therapeutic landscape.<\/span><\/p>\n<p>The IGHV mutational test checks how much the DNA in a specific part of the immune system&#8217;s gene has changed in a group of Chronic Lymphocytic Leukaemia (CLL) cells compared to normal, healthy DNA. This helps doctors understand how the cancer might behave and what treatment options are best.<\/p>\n<p>IGHV mutational status is a factor in determining the prognosis and treatment options for patients with Chronic Lymphocytic Leukaemia (CLL). Testing for IGHV mutations helps classify CLL into two categories: mutated or unmutated, influencing both the disease\u2019s progression and response to therapy. This valuable information aids doctors in creating personalised treatment plans, improving patient outcomes.<\/p>\n<p><strong>Introduction to IGHV Mutational Status Testing in CLL<\/strong><\/p>\n<p>This paper here,\u00a0<a href=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2024\/11\/IGHV-Mutational-Status-Testing-in-Chronic-Lymphocytic-Leukemia.pdf\">IGHV-Mutational-Status-Testing-in-Chronic-Lymphocytic-Leukemia.pdf<\/a> explores in greater depth the role of IGHV mutational status as a biomarker in chronic lymphocytic leukaemia (CLL). By predicting patient outcomes and informing treatment choices, IGHV testing helps guide decisions between chemoimmunotherapy and novel therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This document here, IGHV Mutational Status Testing in Chronic Lymphocytic Leukaemia explains the role of IGHV mutational status testing in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21831,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[126,78,79,81,83,89,95,96],"class_list":["post-21823","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-cancer-drugs-nz","tag-roger-tiedemann-blood-cancer-pharmac","tag-sam-neil-blood-cancer-pharmac","tag-iqvia-report-access-to-medicines-4-atom-4","tag-ruth-spearing","tag-haematology","tag-ben-schrader-cll-advocates-chronic-lymphocyctic-leukaemia","tag-clinical-trials-cll-blood-cancer"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2024\/11\/IGHV_pic_2.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/21823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21823"}],"version-history":[{"count":7,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/21823\/revisions"}],"predecessor-version":[{"id":21949,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/21823\/revisions\/21949"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/21831"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}